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PAST
The incredible rise in melanoma health care costs
urgently demands a reduction in these costs where appro-
priate.1 Nevertheless, cancer patients demand frequent and
close follow-up out of fear of recurrence. Historically,
melanoma patients have been followed regularly, with
limited therapeutic options in case of disease progression.2
In addition, survival benefit as a result of follow-up has
never been demonstrated.3 There is a lack of international
consensus regarding the follow-up frequency of melanoma
patients,4 and evidence regarding the optimal follow-up
frequency of these patients with respect to disease-free and
overall survival, patients’ quality of life (QoL), and costs is
highly needed.
PRESENT
The current randomized controlled MELFO study
compared two groups of stage Ib–IIc melanoma patients,
3 years after diagnosis.5 The first group received follow-up
as advised in the guideline, while the second group
received a stage-adjusted, less frequent follow-up schedule.
Patients’ QoL, anxiety, satisfaction regarding follow-up,
and disease-free and overall survival were comparable, but
a 39% cost reduction was found in those who were less
frequently followed-up. A reduced and stage-adjusted fol-
low-up schedule could be a step forward in better
distribution of resources, such as finances, time, and
manpower.
FUTURE
Several questions need to be answered in the future to
determine the optimal, safe, (cost)-effective follow-up that
will benefit all melanoma patients.3 Apart from recurrence
detection, mental support and patient education are
important after-care goals for melanoma patients with any
stage of disease.6,7 Now that several effective therapeutic
adjuvant systemic treatment options with drug targeting
and/or immunotherapy have become available, follow-up
has become even more complex.8 What is the best strategy
to improve OS in stage IB–II melanoma? Adjuvant therapy
of high-risk stage II patients or treatment at the time of
recurrence? How to select patients who will benefit from
adjuvant treatment while sparing those who are unlikely to
benefit from toxic effects? If melanoma biomarkers could
be identified that can better predict the potential to
metastasize than the current prognostic factors do, a
ASO Author Reflections is a brief invited commentary on the article
‘‘The MELFO-Study: a Multi-Center Prospective Randomized
Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-up
Schedule on Cutaneous Melanoma IB-IIC patients: Results After
3-Years’’, Ann Surg Oncol. In press
 The Author(s) 2019
First Received: 19 June 2019;
Published Online: 3 September 2019
H. J. Hoekstra, MD, PhD
e-mail: h.j.hoekstra@umcg.nl
Ann Surg Oncol (2020) 27:1418–1419
https://doi.org/10.1245/s10434-019-07611-5
personalized follow-up, including emotional support and
patient education, could be delivered even more (cost)
effectively. Currently, stage-adjusted follow-up is the best
personalized follow-up approach for stage IB–II
melanoma.
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